216 related articles for article (PubMed ID: 36536472)
1. Spatiotemporal evolution of the clear cell renal cell carcinoma microenvironment links intra-tumoral heterogeneity to immune escape.
Golkaram M; Kuo F; Gupta S; Carlo MI; Salmans ML; Vijayaraghavan R; Tang C; Makarov V; Rappold P; Blum KA; Zhao C; Mehio R; Zhang S; Godsey J; Pawlowski T; DiNatale RG; Morris LGT; Durack J; Russo P; Kotecha RR; Coleman J; Chen YB; Reuter VE; Motzer RJ; Voss MH; Liu L; Reznik E; Chan TA; Hakimi AA
Genome Med; 2022 Dec; 14(1):143. PubMed ID: 36536472
[TBL] [Abstract][Full Text] [Related]
2. Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma.
Au L; Hatipoglu E; Robert de Massy M; Litchfield K; Beattie G; Rowan A; Schnidrig D; Thompson R; Byrne F; Horswell S; Fotiadis N; Hazell S; Nicol D; Shepherd STC; Fendler A; Mason R; Del Rosario L; Edmonds K; Lingard K; Sarker S; Mangwende M; Carlyle E; Attig J; Joshi K; Uddin I; Becker PD; Sunderland MW; Akarca A; Puccio I; Yang WW; Lund T; Dhillon K; Vasquez MD; Ghorani E; Xu H; Spencer C; López JI; Green A; Mahadeva U; Borg E; Mitchison M; Moore DA; Proctor I; Falzon M; Pickering L; Furness AJS; Reading JL; Salgado R; Marafioti T; Jamal-Hanjani M; ; Kassiotis G; Chain B; Larkin J; Swanton C; Quezada SA; Turajlic S;
Cancer Cell; 2021 Nov; 39(11):1497-1518.e11. PubMed ID: 34715028
[TBL] [Abstract][Full Text] [Related]
3. Identification of a claudin-low subtype in clear cell renal cell carcinoma with implications for the evaluation of clinical outcomes and treatment efficacy.
Zhang C; Li Y; Qian J; Zhu Z; Huang C; He Z; Zhou L; Gong Y
Front Immunol; 2022; 13():1020729. PubMed ID: 36479115
[TBL] [Abstract][Full Text] [Related]
4. Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab.
Riaz N; Havel JJ; Makarov V; Desrichard A; Urba WJ; Sims JS; Hodi FS; Martín-Algarra S; Mandal R; Sharfman WH; Bhatia S; Hwu WJ; Gajewski TF; Slingluff CL; Chowell D; Kendall SM; Chang H; Shah R; Kuo F; Morris LGT; Sidhom JW; Schneck JP; Horak CE; Weinhold N; Chan TA
Cell; 2017 Nov; 171(4):934-949.e16. PubMed ID: 29033130
[TBL] [Abstract][Full Text] [Related]
5. Deciphering Intratumoral Molecular Heterogeneity in Clear Cell Renal Cell Carcinoma with a Radiogenomics Platform.
Udayakumar D; Zhang Z; Xi Y; Dwivedi DK; Fulkerson M; Haldeman S; McKenzie T; Yousuf Q; Joyce A; Hajibeigi A; Notgrass H; de Leon AD; Yuan Q; Lewis MA; Madhuranthakam AJ; Sibley RC; Elias R; Guo J; Christie A; McKay RM; Cadeddu JA; Bagrodia A; Margulis V; Brugarolas J; Wang T; Kapur P; Pedrosa I
Clin Cancer Res; 2021 Sep; 27(17):4794-4806. PubMed ID: 34210685
[TBL] [Abstract][Full Text] [Related]
6. Special issue "The advance of solid tumor research in China": Multi-omics analysis based on 1311 clear cell renal cell carcinoma samples identifies a glycolysis signature associated with prognosis and treatment response.
Tian X; Wang Y; Xu W; Tang H; Zhu S; Anwaier A; Liu W; Wang W; Zhu W; Su J; Qu Y; Zhang H; Ye D
Int J Cancer; 2023 Jan; 152(1):66-78. PubMed ID: 35579992
[TBL] [Abstract][Full Text] [Related]
7. The Significance of PARP1 as a biomarker for Predicting the Response to PD-L1 Blockade in Patients with PBRM1-mutated Clear Cell Renal Cell Carcinoma.
Hagiwara M; Fushimi A; Matsumoto K; Oya M
Eur Urol; 2022 Feb; 81(2):145-148. PubMed ID: 34627641
[TBL] [Abstract][Full Text] [Related]
8. Deciphering the implications of mitophagy-related signatures in clinical outcomes and microenvironment heterogeneity of clear cell renal cell carcinoma.
Xiang J; Liu W; Liu S; Wang T; Tang H; Yang J
J Cancer Res Clin Oncol; 2023 Nov; 149(17):16015-16030. PubMed ID: 37689589
[TBL] [Abstract][Full Text] [Related]
9. Immune-Associated Gene Signatures Serve as a Promising Biomarker of Immunotherapeutic Prognosis for Renal Clear Cell Carcinoma.
Wang Q; Tang H; Luo X; Chen J; Zhang X; Li X; Li Y; Chen Y; Xu Y; Han S
Front Immunol; 2022; 13():890150. PubMed ID: 35686121
[TBL] [Abstract][Full Text] [Related]
10. Ontological analyses reveal clinically-significant clear cell renal cell carcinoma subtypes with convergent evolutionary trajectories into an aggressive type.
Cai Q; Christie A; Rajaram S; Zhou Q; Araj E; Chintalapati S; Cadeddu J; Margulis V; Pedrosa I; Rakheja D; McKay RM; Brugarolas J; Kapur P
EBioMedicine; 2020 Jan; 51():102526. PubMed ID: 31859241
[TBL] [Abstract][Full Text] [Related]
11. Immunomodulatory response to neoadjuvant nivolumab in non-metastatic clear cell renal cell carcinoma.
Singla N; Nirschl TR; Obradovic AZ; Shenderov E; Lombardo K; Liu X; Pons A; Zarif JC; Rowe SP; Trock BJ; Hammers HJ; Bivalacqua TJ; Pierorazio PM; Deutsch JS; Lotan TL; Taube JM; Ged YMA; Gorin MA; Allaf ME; Drake CG
Sci Rep; 2024 Jan; 14(1):1458. PubMed ID: 38228729
[TBL] [Abstract][Full Text] [Related]
12. Differential treatment responses to immune checkpoint inhibitor (ICI) therapy in a case of multiple primary malignancies: the programmed death ligand-1 (PD-L1) negative ureteral and lung metastasis from a clear cell renal cell carcinoma appearing after robotic-assisted partial nephrectomy progressed after ICI therapy, while synchronous PD-L1-positive primary lung squamous cell carcinoma responded very well to ICI therapy: a case report.
Urushibara M; Ishizaka K; Matsutani N; Takahashi M; Nagata M; Okumura T; Matsumoto Y; Tatsuoka S; Nenohi T; Amemiya T; Shimizu Y; Shirakawa T; Kato D
World J Surg Oncol; 2023 Feb; 21(1):37. PubMed ID: 36747242
[TBL] [Abstract][Full Text] [Related]
13. Low intratumor heterogeneity correlates with increased response to PD-1 blockade in renal cell carcinoma.
Ran X; Xiao J; Zhang Y; Teng H; Cheng F; Chen H; Zhang K; Sun Z
Ther Adv Med Oncol; 2020; 12():1758835920977117. PubMed ID: 33425025
[TBL] [Abstract][Full Text] [Related]
14. An Enhancer Demethylator Phenotype Converged to Immune Dysfunction and Resistance to Immune Checkpoint Inhibitors in Clear-Cell Renal Cell Carcinomas.
Lu X; Vano Y; Helleux A; Su X; Lindner V; Davidson G; Mouawad R; Spano JP; Rouprêt M; Elaidi R; Compérat E; Verkarre V; Sun C; Chevreau C; Bennamoun M; Lang H; Tricard T; Cheng W; Xu L; Davidson I; Yan F; Fridman WH; Sautes-Fridman C; Oudard S; Malouf GG
Clin Cancer Res; 2023 Apr; 29(7):1279-1291. PubMed ID: 36374555
[TBL] [Abstract][Full Text] [Related]
15. Immune inactivation by CD47 expression predicts clinical outcomes and therapeutic responses in clear cell renal cell carcinoma patients.
Jiang W; Zeng H; Liu Z; Jin K; Hu B; Chang Y; Liu L; Zhu Y; Xu L; Wang Z; Guo J; Xu J
Urol Oncol; 2022 Apr; 40(4):166.e15-166.e25. PubMed ID: 34998671
[TBL] [Abstract][Full Text] [Related]
16. Ultra-deep T cell receptor sequencing reveals the complexity and intratumour heterogeneity of T cell clones in renal cell carcinomas.
Gerlinger M; Quezada SA; Peggs KS; Furness AJ; Fisher R; Marafioti T; Shende VH; McGranahan N; Rowan AJ; Hazell S; Hamm D; Robins HS; Pickering L; Gore M; Nicol DL; Larkin J; Swanton C
J Pathol; 2013 Dec; 231(4):424-32. PubMed ID: 24122851
[TBL] [Abstract][Full Text] [Related]
17. Spatial heterogeneity of tumor microenvironment influences the prognosis of clear cell renal cell carcinoma.
Zhang D; Ni Y; Wang Y; Feng J; Zhuang N; Li J; Liu L; Shen W; Zheng J; Zheng W; Qian C; Shan J; Zhou Z
J Transl Med; 2023 Jul; 21(1):489. PubMed ID: 37474942
[TBL] [Abstract][Full Text] [Related]
18. Prognostic and Predictive Value of Tumor-infiltrating Leukocytes and of Immune Checkpoint Molecules PD1 and PDL1 in Clear Cell Renal Cell Carcinoma.
Stenzel PJ; Schindeldecker M; Tagscherer KE; Foersch S; Herpel E; Hohenfellner M; Hatiboglu G; Alt J; Thomas C; Haferkamp A; Roth W; Macher-Goeppinger S
Transl Oncol; 2020 Feb; 13(2):336-345. PubMed ID: 31881506
[TBL] [Abstract][Full Text] [Related]
19. ARHGAP11A Is a Novel Prognostic and Predictive Biomarker Correlated with Immunosuppressive Microenvironment in Clear Cell Renal Cell Carcinoma.
Yang H; Zhang H; Zhang L; Tusuphan P; Zheng J
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175461
[TBL] [Abstract][Full Text] [Related]
20. Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma.
Denize T; Hou Y; Pignon JC; Walton E; West DJ; Freeman GJ; Braun DA; Wu CJ; Gupta S; Motzer RJ; Atkins MB; McDermott D; Choueiri TK; Shukla SA; Signoretti S
Clin Cancer Res; 2022 Sep; 28(18):4045-4055. PubMed ID: 35802667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
